查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年生物仿製药市场预测 - 按药物类别、製造类型、技术、用途、最终用户和地区进行的全球分析
市场调查报告书
商品编码
1339987

2030 年生物仿製药市场预测 - 按药物类别、製造类型、技术、用途、最终用户和地区进行的全球分析

Biosimilars Market Forecasts to 2030 - Global Analysis By Drug Class, Manufacturing Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

据Stratistics MRC预测，2023年全球生物仿製药市场规模将达到239亿美元，预计到2030年将达到1002亿美元，预测期内年复合成长率为22.7%。

生物仿製药，也称为后续生物製品，几乎是原研药的精确复製品，但由不同的公司生产。多种急性和慢性疾病和病症正在用生物仿製药进行治疗。使用生物仿製药捕获人脑的电活动。

根据国际癌症研究机构2020的数据，2020年全球新增白血病患者人数预计为474,519人。

市场动态：

促进因素

  • 强大的产品平臺。
  • 拥有强大生物仿製药产品线的製药公司处于有利地位，可以满足对具有成本效益的生物製剂替代品不断增长的需求。我们多样化且广泛的产品线涵盖各种治疗领域和病理，从而提供更广泛的治疗选择。随着越来越多的生物製剂专利到期，强大的产品平臺提供了新的生物仿製药的稳定来源，从而增加了市场竞争和可用性。

抑制因素

  • 开发成本高。
  • 开发生物仿製药是一个复杂且资源集中的过程，需要广泛的研究、临床试验和监管部门的批准。生物仿製药的开发需要广泛的研究、临床试验和监管部门的批准，公司必须通过广泛的测试证明生物仿製药与参考生物製剂具有可比性，这是不可能的。此外，生物仿製药的法规环境通常比仿製药有更严格的要求，这可能会进一步增加开发成本。这些高成本可能会阻止一些製药公司进入生物仿製药市场，限制市场竞争，并延迟向患者提供更便宜的生物仿製药。

机会：

  • 对生物仿製药的需求不断增长。
  • 生物仿製药是昂贵生物製剂的经济高效替代品，具有相似的治疗功效和质量。随着医疗保健成本的不断上升以及对负担得起的治疗选择的需求，生物仿製药在医疗保健提供者和患者中越来越受欢迎。世界各地的政府和医疗保健系统都鼓励使用生物仿製药来改善救生药物的获取并降低医疗保健成本。随着越来越多的生物製剂专利到期，生物仿製药市场正在迅速扩大，扩大了患者获得重要治疗的机会，并使製药公司有能力在这个快速增长和充满活力的领域竞争。希望会有机会这样做。

威胁：

  • 製造复杂性。
  • 与传统的小分子药物不同，生物类似药是在活细胞中製造的复杂生物化合物，其製造过程复杂而精细。细胞株、发酵、精製和翻译后变化只是必须仔细控制以确保质量、功效和安全性一致性的众多变量中的几个。任何製造偏差或差异都可能影响最终产品与参考生物製品的相似性并威胁患者安全。与生物仿製药相关的严格法规限制和高昂的研究成本带来了额外的挑战，阻碍了一些公司进入市场，并限制了对患者友好的生物仿製药替代品的供应。

COVID-19 的影响：

  • 由于许多国家实施了封锁，预计 COVID-19 大流行将对生物仿製药市场的增长产生负面影响。 COVID-19 大流行使製药行业无法专注于研发，尤其是生物仿製药的研发。疫情期间，整个医疗保健行业都专注于开发救生产品。此外，疫情导致产品审批和上市延迟，进一步限制了生物仿製药行业的增长。
  • 重组非糖基化蛋白片段预计在预测期内将是最大的
  • 重组非糖基化蛋白片段是一类重要的生物製剂，用于治疗癌症、自身免疫性疾病和炎症性疾病等多种疾病，因此生物仿製药市场预计将出现良好增长。非糖基化蛋白质的生物仿製药开发是一个很有前途的机会，可以为昂贵的参考生物製剂提供具有成本效益的替代品。一旦非糖基化生物製剂的专利到期，生物仿製药製造商可以利用这个机会为患者提供更便宜的治疗选择。然而，製造复杂性以及展示与参考产品的可比性给开发和批准过程带来了挑战。
  • 癌症领域预计在预测期内復合年复合成长率最高
  • 肿瘤学预计在预测期内復合年复合成长率最快。随着全球癌症罹患率的上升，生物製剂已成为癌症领域不可或缺的一部分，但其高昂的成本给许多患者带来了挑战。生物仿製药提供了一种有前途的解决方案，为癌症治疗中使用的昂贵生物製剂提供了更实惠的替代品。随着各种癌症生物製剂的专利到期，生物仿製药开发商正专注于开发等效製剂，扩大医疗保健提供者和患者的选择范围。

占比最大的地区

预计北美生物仿製药市场在预测期内将继续占据大部分市场份额。这是由于人们越来越关注先进的医疗基础设施和具有成本效益的治疗方案。随着一些生物製剂失去专利独占权，该地区生物仿製药的批准和市场准入有所增加。美国生物製品价格竞争和创新法案（BPCIA）等法规框架为生物仿製药的开发和商业化铺平了道路。此外，製药公司和医疗保健提供者之间的合作正在进一步推动生物仿製药的采用。

复合年复合成长率最高的地区：

预计亚太地区在预测期内年复合成长率最高。慢性病的增加、医疗保健成本的上升以及专利到期的生物製剂正在推动对具有成本效益的治疗方案的需求。印度、韩国和中国等政府正在积极推动生物仿製药的采用，以提高医疗保健的可及性和可负担性。此外，支持性的法规环境和简化的审批流程正在鼓励国内外製药公司投资生物仿製药开发。

免费定制服务：

订阅此报告的客户将收到以下免费定制选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（注：基于可行性检查）
  • 竞争标杆管理
    • 根据产品系列、地域分布和战略联盟对主要企业进行基准测试

目录

第1章执行摘要

第2章前言

  • 概述
  • 利益相关者
  • 调查范围
  • 调查方法
    • 资料挖掘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球生物仿製药市场：按药物类别

  • 重组非糖基化蛋白
    • 重组人生长激素
    • 颗粒细胞增生因子
    • 胰岛素
    • 干扰素
  • 重组糖基化蛋白
    • 促红细胞生成素
    • 单克隆抗体
      • 英夫利昔单抗
      • 利妥昔单抗
      • 阿达木单抗
      • 曲妥珠单抗
      • Bevacizumab
      • 依那西普
    • 促卵泡素
  • 重组肽
    • 依那西普
    • 特立帕肽
    • 抗凝物
  • 其他药物类别

第6章全球生物仿製药市场：按製造类型

  • 自主生产
  • 合同起草（名词

第7章全球生物仿製药市场：按技术分类

  • 质谱
  • 色谱法
  • 单克隆抗体技术
  • 重组DNA技术
  • 核磁共振（NMR）技术
  • 电泳
  • 生物测定

第8章全球生物仿製药市场：按用途

  • 血液学
    • 中性粒细胞减少症
    • 贫血
  • 肿瘤学
    • 肺癌
    • 脑肿瘤
    • 乳腺癌
    • 宫颈癌
    • 结直肠癌
    • 白血病
      • 非霍奇金淋巴瘤 (NHL)
      • 慢性淋巴性白血病（CLL）
  • 慢性病
  • 自身免疫性疾病
    • 关节炎
      • 类风湿性关节炎
      • 干癣性关节炎
      • 幼年型关节炎
      • 僵直性脊椎炎
    • 炎症性肠病（IBD）
      • 溃疡性大肠炎
      • 克罗恩病
    • 银屑病
  • 血液疾病
  • 生长激素缺乏症
  • 糖尿病
  • 其他用途

第9章全球生物仿製药市场：按最终用户分类

  • 医院药房
  • 零售药房
  • 网上药房
  • 其他最终用户

第10章全球生物仿製药市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第11章进展

  • 合同、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第12章公司简介

  • Coherus Biosciences Inc.
  • Boehringer Ingelheim International GMBH
  • Eli Lilly and Company
  • Fresenius Kabi Ag
  • Samsung Bioepis Co. Ltd
  • Amgen Inc.
  • LG Life Sciences（LG Chem）
  • Celltrion Healthcare
  • Biocad
  • Dr. Reddy's Laboratories LTD.
  • Viatris Inc.
  • Intas Pharmaceutical Ltd
  • Biocon Limited
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc.
  • Stada Arzneimittel AG
  • Novartis AG
Product Code: SMRC23694

According to Stratistics MRC, the Global Biosimilars Market is accounted for $23.9 billion in 2023 and is expected to reach $100.2 billion by 2030 growing at a CAGR of 22.7% during the forecast period. Biosimilars, also known as follow-on biologics, are almost exact replicas of the original drugs but are created by a different company. A variety of acute and chronic illnesses and disorders are treated with biosimilars.

According to the International Agency for Research on Cancer 2020, the estimated number of new leukemia cases in 2020 was 474,519 globally.

Market Dynamics:

Driver:

  • Strong product pipeline.
  • Pharmaceutical companies with robust pipelines of biosimilar products are well-positioned to meet the increasing demand for cost-effective alternatives to biologic drugs. A diverse and expansive pipeline allows for a broader range of therapeutic options, covering various therapeutic areas and medical conditions. As more biologic drugs approach patent expiration, a well-developed product pipeline can lead to a steady stream of new biosimilar offerings, enhancing competition and availability in the market.

Restraint:

  • High developmental costs.
  • Developing a biosimilar is a complex and resource-intensive process that involves extensive research, clinical trials, and regulatory approvals. Companies must demonstrate the biosimilar's comparability to the reference biologic through extensive testing, which requires substantial financial investment. Additionally, navigating the regulatory landscape for biosimilars, which often involves more stringent requirements compared to generic drugs, can further escalate development costs. These high costs deter some pharmaceutical companies from entering the biosimilars market, leading to limited competition and potentially delaying the availability of more affordable biosimilar alternatives for patients.

Opportunity:

  • Increasing demand for biosimilars.
  • Biosimilars are cost-effective alternatives to expensive biologic drugs, offering similar therapeutic effects and quality. With rising healthcare costs and the need for affordable treatment options, biosimilars have gained traction among healthcare providers and patients. Governments and healthcare systems worldwide are encouraging the use of biosimilars to enhance accessibility to life-saving medications and reduce healthcare expenditure. As more biologic drugs approach patent expiration, the biosimilars market is expected to expand rapidly, providing patients with greater access to critical treatments and creating opportunities for pharmaceutical companies to compete in this growing and dynamic sector.

Threat:

  • Complexities in manufacturing.
  • Biosimilars are complex biologic compounds made in living cells as opposed to conventional small-molecule medications, making the production procedure for them complex and delicate. Cell lines, fermentation, purification, and post-translational changes are just a few of the many variables that need to be carefully controlled in order to guarantee consistency in quality, effectiveness, and safety. Any manufacturing deviation or inconsistency might affect the final product's resemblance to the reference biologic and potentially jeopardize patient safety. The strict regulatory restrictions and expensive research costs related to biosimilars provide additional difficulties, deterring some businesses from joining the market and limiting the supply of patient-friendly biosimilar substitutes.

COVID-19 Impact:

  • The COVID-19 outbreak is anticipated to have a negative impact on the growth of the biosimilars market, owing to the implementation of lockdowns in many countries. The COVID-19 pandemic made it impossible for the pharmaceutical sector to concentrate on R&D efforts, particularly the creation of biosimilars. During the epidemic, the whole healthcare sector has concentrated on developing life-saving products. Additionally, pandemic conditions cause delays in product approvals and releases, which further limit the growth of the biosimilars industry.
  • The recombinant non-glycosylated proteins segment is expected to be the largest during the forecast period
  • The recombinant non-glycosylated proteins segment is expected to have lucrative growth in the biosimilars market as they represent a crucial class of biologic drugs used to treat various diseases, including cancer, autoimmune disorders, and inflammatory conditions. Biosimilar development for non-glycosylated proteins presents a promising opportunity to offer cost-effective alternatives to expensive reference biologics. As patents for non-glycosylated biologics expire, biosimilar manufacturers can capitalize on this opportunity to provide more affordable treatment options for patients. However, the complexity of manufacturing and demonstrating comparability to the reference products pose challenges in the development and approval processes.
  • The oncology segment is expected to have the highest CAGR during the forecast period
  • The oncology segment is anticipated to witness the fastest CAGR growth during the forecast period. With the rising incidence of cancer worldwide, biologic drugs have become essential in the oncology field, but their high costs pose challenges for many patients. Biosimilars offer a promising solution by providing more affordable alternatives to expensive biologics used in cancer therapies. As patents for various oncology biologics expire, biosimilar developers have focused on developing comparable versions, expanding the options available to healthcare providers and patients.

Region with largest share:

During the forecast period, it is expected that the North American Biosimilars market will continue to hold a majority of the market share. Due to its advanced healthcare infrastructure and growing focus on cost-effective treatment options. With several biologic drugs losing patent exclusivity, the region has seen an increase in biosimilars approvals and market entry. Regulatory frameworks, such as the Biologics Price Competition and Innovation Act (BPCIA) in the United States, have paved the way for biosimilars development and commercialization. Moreover, collaborations between pharmaceutical companies and healthcare providers have further facilitated biosimilars adoption.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. The increasing prevalence of chronic diseases, rising healthcare costs, and the expiration of biologic drug patents has fuelled the demand for cost-effective treatment options. Governments in countries like India, South Korea, and China are actively promoting the adoption of biosimilars to enhance healthcare accessibility and affordability. Additionally, a supportive regulatory environment and streamlined approval processes have encouraged both domestic and international pharmaceutical companies to invest in biosimilar development.

Key players in the market:

Some of the key players in Biosimilars market include: Coherus Biosciences Inc., Boehringer Ingelheim International GMBH, Eli Lilly and Company, Fresenius Kabi Ag, Samsung Bioepis Co. Ltd, Amgen Inc., LG Life Sciences (LG Chem), Celltrion Healthcare, Biocad, Dr. Reddy's Laboratories LTD., Viatris Inc., Intas Pharmaceutical Ltd, Biocon Limited, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Stada Arzneimittel AG and Novartis AG.

Key Developments:

  • In May 2023, Boehringer Ingelheim received U.S. FDA clearance for Cyltezo Pen, a novel autoinjector choice for Cyltezo (adalimumab-adbm), an FDA-approved interchangeable biosimilar to Humira.
  • In January 2023, Amgen Inc. launched AMJEVITA (adalimumab-atto), a biosimilar to Humira (adalimumab) in United States.
  • In October 2022, Biocon and Yoshindo Inc., entered into an agreement for commercializing Biocon's pipeline products ustekinumab and bDenosumab in Japan.

Drug Classes Covered:

  • Recombinant Non-Glycosylated Proteins
  • Recombinant Glycosylated Proteins
  • Recombinant Peptides
  • Other Drug Classes

Manufacturing Types Covered:

  • In-house Manufacturing
  • Contract Manufacturing

Technologies Covered:

  • Mass Spectroscopy
  • Chromatography
  • Monoclonal Antibody Technology
  • Recombinant DNA Technology
  • Nuclear Magnetic Resonance (NMR) Technology
  • Electrophoresis
  • Bioassay

Applications Covered:

  • Hematology
  • Oncology
  • Chronic Diseases
  • Autoimmune Disease
  • Blood Disorders
  • Growth Hormone Deficiency
  • Diabetes
  • Other Applications

End Users Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biosimilars Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Recombinant Non-Glycosylated Proteins
    • 5.2.1 Recombinant Human Growth Hormone
    • 5.2.2 Granulocyte Colony-Stimulating Factor
    • 5.2.3 Insulin
    • 5.2.4 Interferons
  • 5.3 Recombinant Glycosylated Proteins
    • 5.3.1 Erythropoietin
    • 5.3.2 Monoclonal Antibodies
      • 5.3.2.1 Infliximab
      • 5.3.2.2 Rituximab
      • 5.3.2.3 Adalimumab
      • 5.3.2.4 Trastuzumab
      • 5.3.2.5 Bevacizumab
      • 5.3.2.6 Etanercept
    • 5.3.3 Follitropin
  • 5.4 Recombinant Peptides
    • 5.4.1 Etanercept
    • 5.4.2 Teriparatide
    • 5.4.3 Anticoagulants
  • 5.5 Other Drug Classes

6 Global Biosimilars Market, By Manufacturing Type

  • 6.1 Introduction
  • 6.2 In-house Manufacturing
  • 6.3 Contract Manufacturing

7 Global Biosimilars Market, By Technology

  • 7.1 Introduction
  • 7.2 Mass Spectroscopy
  • 7.3 Chromatography
  • 7.4 Monoclonal Antibody Technology
  • 7.5 Recombinant DNA Technology
  • 7.6 Nuclear Magnetic Resonance (NMR) Technology
  • 7.7 Electrophoresis
  • 7.8 Bioassay

8 Global Biosimilars Market, By Application

  • 8.1 Introduction
  • 8.2 Hematology
    • 8.2.1 Neutropenia
    • 8.2.2 Anemia
  • 8.3 Oncology
    • 8.3.1 Lung Cancer
    • 8.3.2 Brain Cancer
    • 8.3.3 Breast Cancer
    • 8.3.4 Cervical Cancer
    • 8.3.5 Colorectal Cancer
    • 8.3.6 Leukemia
      • 8.3.6.1 Non-Hodgkin Lymphoma (NHL)
      • 8.3.6.2 Chronic Lymphocytic Leukemia (CLL)
  • 8.4 Chronic Diseases
  • 8.5 Autoimmune Disease
    • 8.5.1 Arthritis
      • 8.5.1.1 Rheumatoid Arthritis
      • 8.5.1.2 Psoriatic Arthritis
      • 8.5.1.3 Juvenile Arthritis
      • 8.5.1.4 Ankylosing Spondylitis
    • 8.5.2 Inflammatory Bowel Disease (IBD)
      • 8.5.2.1 Ulcerative Colitis
      • 8.5.2.2 Crohn's Disease
    • 8.5.3 Psoriasis
  • 8.6 Blood Disorders
  • 8.7 Growth Hormone Deficiency
  • 8.8 Diabetes
  • 8.9 Other Applications

9 Global Biosimilars Market, By End User

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies
  • 9.5 Other End Users

10 Global Biosimilars Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Coherus Biosciences Inc.
  • 12.2 Boehringer Ingelheim International GMBH
  • 12.3 Eli Lilly and Company
  • 12.4 Fresenius Kabi Ag
  • 12.5 Samsung Bioepis Co. Ltd
  • 12.6 Amgen Inc.
  • 12.7 LG Life Sciences (LG Chem)
  • 12.8 Celltrion Healthcare
  • 12.9 Biocad
  • 12.10 Dr. Reddy's Laboratories LTD.
  • 12.11 Viatris Inc.
  • 12.12 Intas Pharmaceutical Ltd
  • 12.13 Biocon Limited
  • 12.14 Teva Pharmaceutical Industries Ltd
  • 12.15 Pfizer Inc.
  • 12.16 Stada Arzneimittel AG
  • 12.17 Novartis AG

List of Tables

  • Table 1 Global Biosimilars Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Biosimilars Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 3 Global Biosimilars Market Outlook, By Recombinant Non-Glycosylated Proteins (2021-2030) ($MN)
  • Table 4 Global Biosimilars Market Outlook, By Recombinant Human Growth Hormone (2021-2030) ($MN)
  • Table 5 Global Biosimilars Market Outlook, By Granulocyte Colony-Stimulating Factor (2021-2030) ($MN)
  • Table 6 Global Biosimilars Market Outlook, By Insulin (2021-2030) ($MN)
  • Table 7 Global Biosimilars Market Outlook, By Interferons (2021-2030) ($MN)
  • Table 8 Global Biosimilars Market Outlook, By Recombinant Glycosylated Proteins (2021-2030) ($MN)
  • Table 9 Global Biosimilars Market Outlook, By Erythropoietin (2021-2030) ($MN)
  • Table 10 Global Biosimilars Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 11 Global Biosimilars Market Outlook, By Follitropin (2021-2030) ($MN)
  • Table 12 Global Biosimilars Market Outlook, By Recombinant Peptides (2021-2030) ($MN)
  • Table 13 Global Biosimilars Market Outlook, By Etanercept (2021-2030) ($MN)
  • Table 14 Global Biosimilars Market Outlook, By Teriparatide (2021-2030) ($MN)
  • Table 15 Global Biosimilars Market Outlook, By Anticoagulants (2021-2030) ($MN)
  • Table 16 Global Biosimilars Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 17 Global Biosimilars Market Outlook, By Manufacturing Type (2021-2030) ($MN)
  • Table 18 Global Biosimilars Market Outlook, By In-house Manufacturing (2021-2030) ($MN)
  • Table 19 Global Biosimilars Market Outlook, By Contract Manufacturing (2021-2030) ($MN)
  • Table 20 Global Biosimilars Market Outlook, By Technology (2021-2030) ($MN)
  • Table 21 Global Biosimilars Market Outlook, By Mass Spectroscopy (2021-2030) ($MN)
  • Table 22 Global Biosimilars Market Outlook, By Chromatography (2021-2030) ($MN)
  • Table 23 Global Biosimilars Market Outlook, By Monoclonal Antibody Technology (2021-2030) ($MN)
  • Table 24 Global Biosimilars Market Outlook, By Recombinant DNA Technology (2021-2030) ($MN)
  • Table 25 Global Biosimilars Market Outlook, By Nuclear Magnetic Resonance (NMR) Technology (2021-2030) ($MN)
  • Table 26 Global Biosimilars Market Outlook, By Electrophoresis (2021-2030) ($MN)
  • Table 27 Global Biosimilars Market Outlook, By Bioassay (2021-2030) ($MN)
  • Table 28 Global Biosimilars Market Outlook, By Application (2021-2030) ($MN)
  • Table 29 Global Biosimilars Market Outlook, By Hematology (2021-2030) ($MN)
  • Table 30 Global Biosimilars Market Outlook, By Neutropenia (2021-2030) ($MN)
  • Table 31 Global Biosimilars Market Outlook, By Anemia (2021-2030) ($MN)
  • Table 32 Global Biosimilars Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 33 Global Biosimilars Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 34 Global Biosimilars Market Outlook, By Brain Cancer (2021-2030) ($MN)
  • Table 35 Global Biosimilars Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 36 Global Biosimilars Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 37 Global Biosimilars Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 38 Global Biosimilars Market Outlook, By Leukemia (2021-2030) ($MN)
  • Table 39 Global Biosimilars Market Outlook, By Chronic Diseases (2021-2030) ($MN)
  • Table 40 Global Biosimilars Market Outlook, By Autoimmune Disease (2021-2030) ($MN)
  • Table 41 Global Biosimilars Market Outlook, By Arthritis (2021-2030) ($MN)
  • Table 42 Global Biosimilars Market Outlook, By Inflammatory Bowel Disease (IBD) (2021-2030) ($MN)
  • Table 43 Global Biosimilars Market Outlook, By Psoriasis (2021-2030) ($MN)
  • Table 44 Global Biosimilars Market Outlook, By Blood Disorders (2021-2030) ($MN)
  • Table 45 Global Biosimilars Market Outlook, By Growth Hormone Deficiency (2021-2030) ($MN)
  • Table 46 Global Biosimilars Market Outlook, By Diabetes (2021-2030) ($MN)
  • Table 47 Global Biosimilars Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 48 Global Biosimilars Market Outlook, By End User (2021-2030) ($MN)
  • Table 49 Global Biosimilars Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 50 Global Biosimilars Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 51 Global Biosimilars Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 52 Global Biosimilars Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.